RBC Capital Maintains Outperform on United Therapeutics, Lowers Price Target to $701

Benzinga Newsdesk www.benzinga.com Negative 95.2%

Neg 95.2% Neu 0% Pos 0%

RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and lowers the price target from $707 to $701.